ArticleOncoTargets and therapy2013
Current management options for recurrent adrenocortical carcinoma.
Article in OncoTargets and therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 45 citations in OpenAlex.
- A Phase II Trial of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Adrenocortical Carcinoma.The Journal of surgical research · 2018Trial
- Patient Experience of Adrenocortical Carcinoma: Views from a Patient, His Physician and a Patient Association.Advances in therapy · 2026Article
- Bilateral adrenal tumors presenting with Cushing syndrome in the setting of horseshoe kidney: surgical and urological considerations (case report).The Pan African medical journal · 2025Article
- Loco-regional recurrence of adrenocortical carcinoma: A case report.International journal of surgery case reports · 2024Article
- Expression of EMP 1, 2, and 3 in Adrenal Cortical Neoplasm and Pheochromocytoma.International journal of molecular sciences · 2023Article
- The underlying molecular mechanism and drugs for treatment in adrenal cortical carcinoma.International journal of medical sciences · 2021Article
- Oligometastatic adrenocortical carcinoma: the role of image-guided thermal ablation.European radiology · 2020Article
- Hyperthermic Intraperitoneal Chemotherapy for Primary or Recurrent Adrenocortical Carcinoma. A Single Center Study.Cancers · 2020Article
- Successful treatment of metastatic adrenocortical carcinoma in the spine: A case report and literature review.Medicine · 2019Review
- Management of Adrenocortical Carcinoma.Current oncology reports · 2019Review
- Cholesterol as an Endogenous ERRα Agonist: A New Perspective to Cancer Treatment.Frontiers in endocrinology · 2018Review
- GPER-independent inhibition of adrenocortical cancer growth by G-1 involves ROS/Egr-1/BAX pathway.Oncotarget · 2017Article
- Adrenocortical carcinoma: Single center experience.Turkish journal of urology · 2017Article
- Article
- Synchronous vs. Metachronous Metastases in Adrenocortical Carcinoma: an Analysis of the Dutch Adrenal Network.Hormones & cancer · 2016Article
- Adrenocortical cancer: mortality, hormone secretion, proliferation and urine steroids - experience from a single centre spanning three decades.BMC endocrine disorders · 2016Article
- Prognostic Factors for Adrenocortical Carcinoma Outcomes.Frontiers in endocrinology · 2016Article
- Synthetic high-density lipoprotein nanoparticles: A novel therapeutic strategy for adrenocortical carcinomas.Surgery · 2016Article
- Estrogen related receptor α (ERRα) a promising target for the therapy of adrenocortical carcinoma (ACC).Oncotarget · 2015Article
- Clinical and pathological analysis of 116 cases of adult adrenal cortical adenoma and literature review.OncoTargets and therapy · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adrenal cortical carcinoma (ACC) is a rare cancer that poses a number of management challenges due to the limited number of effective systemic treatments. Complete surgical resection offers the best chance of long-term survival. However, despite complete resection, ACC is associated with high recurrence rates. This review will discuss the management of recurrent ACC in adults following complete surgical resection. Management should take place in a specialist center and treatment decisions must consider the individual tumor biology of each case of recurrence. Given the fact that ACC commonly recurs, management to prevent recurrence should be considered from initial diagnosis with the use of adjuvant mitotane. Close follow up with clinical examination and imaging is important for early detection of recurrent disease. Locoregional recurrence may be isolated, and repeat surgical resection should be considered along with mitotane. The use of radiotherapy in ACC remains controversial. Systemic recurrence most often involves liver, pulmonary, and bone metastasis and is usually managed with mitotane, with or without combination chemotherapy. There is a limited role for surgical resection in systemic recurrence in selected patients. In all patients with recurrent disease, control of excessive hormone production is an important part of management. Despite intensive management of recurrent ACC, treatment failure is common and the use of clinical trials and novel treatment is an important part of management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.